• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SWK Holdings Corporation Announces Pricing of Public Offering of Senior Unsecured Notes Due 2027

    9/28/23 6:34:00 PM ET
    $SWKH
    Diversified Financial Services
    Finance
    Get the next $SWKH alert in real time by email

    DALLAS, Sept. 28, 2023 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ: SWKH) ("SWK" or the "Company") today announced that it has priced its previously announced registered underwritten public offering (the "Offering") of $30 million in aggregate principal amount of 9.00% Senior notes due 2027 (the "Notes"). SWK has also granted the underwriters of the Offering an option to purchase up to an additional $4.5 million in aggregate principal amount of the Notes. The total net proceeds from the Offering (excluding exercise of the underwriter option) are approximately $29.1 million (after deducting underwriting discounts and commissions, but before other fees and estimated expenses). 

    The Notes will mature on January 31, 2027, unless earlier redeemed, and will bear interest at a rate of 9.00% per annum, payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each year and at maturity, commencing on December 31, 2023.

    SWK intends to use the net proceeds from the Offering for general corporate purposes, including funding future acquisitions and investments, repaying indebtedness, making capital expenditures and funding working capital. The Notes will be issued in minimum denominations of $25.00 and integral multiples of $25.00 in excess thereof. SWK and the Notes have been rated BBB- by Egan-Jones Ratings Company, an independent rating agency. The Offering is expected to close on October 3, 2023, subject to the satisfaction of customary closing conditions.

    In connection with the Offering, SWK has applied to list the Notes on the Nasdaq Global Market ("Nasdaq") under the symbol "SWKHL". If approved for listing, trading on Nasdaq is expected to commence on October 4, 2023.

    B. Riley Securities, Inc., Ladenburg Thalmann & Co. Inc. and William Blair & Company, L.L.C. are acting as joint book-running managers for the Offering. InspereX LLC and Maxim Group LLC are acting as co-managers for the Offering.

    This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Notes may only be offered and sold under SWK's registration statement on Form S-1 (including a preliminary prospectus), as amended and as may be supplemented by any free writing prospectus that the Company may file with the Securities and Exchange Commission ("SEC"), which has been filed with the SEC and declared effective on September 28, 2023. Copies of the registration statement may be obtained on the SEC's website at www.sec.gov or by contacting B. Riley Securities, Inc. by phone at (703) 312-9580 or by emailing [email protected].

    About SWK Holdings Corporation

    SWK Holdings Corporation is a life science focused specialty finance company partnering with small- and mid-sized commercial-stage healthcare companies. SWK provides non-dilutive financing to fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products. SWK's unique financing structures provide flexible financing solutions at an attractive cost of capital to create long-term value for all SWK stakeholders. SWK's solutions include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases typically ranging in size from $5.0 million to $25.0 million. SWK also owns Enteris BioPharma, a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence® platform.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intend," "guidance," "future" or similar expressions are forward-looking statements. Because these statements reflect SWK's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties, including uncertainties related to the completion of the Offering on the anticipated terms or at all. Investors should note that many factors, as more fully described under the caption "Risk Factors" and elsewhere in SWK's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein, could affect the Company's future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause the Company's actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

    Cision View original content:https://www.prnewswire.com/news-releases/swk-holdings-corporation-announces-pricing-of-public-offering-of-senior-unsecured-notes-due-2027-301942411.html

    SOURCE SWK Holdings Corporation

    Get the next $SWKH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SWKH

    DatePrice TargetRatingAnalyst
    12/28/2022$26.00Buy
    Lake Street
    4/18/2022$26.00Buy
    Lake Street
    More analyst ratings

    $SWKH
    SEC Filings

    View All

    SEC Form 15-12G filed by SWK Holdings Corporation

    15-12G - SWK Holdings Corp (0001089907) (Filer)

    4/16/26 4:15:08 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    SEC Form EFFECT filed by SWK Holdings Corporation

    EFFECT - SWK Holdings Corp (0001089907) (Filer)

    4/9/26 12:15:04 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    SEC Form EFFECT filed by SWK Holdings Corporation

    EFFECT - SWK Holdings Corp (0001089907) (Filer)

    4/9/26 12:15:02 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street resumed coverage on SWK Holdings with a new price target

    Lake Street resumed coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00

    12/28/22 9:18:49 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    Lake Street initiated coverage on SWK Holdings with a new price target

    Lake Street initiated coverage of SWK Holdings with a rating of Buy and set a new price target of $26.00

    4/18/22 8:44:23 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Carlson Capital, L.P.

    4 - SWK Holdings Corp (0001089907) (Issuer)

    4/8/26 7:00:09 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    Director Hatcher Robert K. was granted 3,858 shares, increasing direct ownership by 30% to 16,662 units (SEC Form 4)

    4 - SWK Holdings Corp (0001089907) (Issuer)

    6/18/25 8:16:45 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    Director Albright Jerry was granted 3,858 shares, increasing direct ownership by 55% to 10,832 units (SEC Form 4)

    4 - SWK Holdings Corp (0001089907) (Issuer)

    6/18/25 8:16:24 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Runway Growth Finance Corp. to Acquire SWK Holdings Corporation

    Acquisition of high-quality portfolio centered on healthcare and life sciences investments Accelerates strategy to diversify and optimize portfolio while adding significant scale Enhances financial profile and is expected to be accretive to net investment income ("NII") MENLO PARK, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (NASDAQ:RWAY) ("Runway Growth" or the "Company"), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today announced that it has entered into a definitive merger agreement to acquire SWK Holdings Corporation (NASDAQ:SWKH) ("SWK"), a life science focused specialty fi

    10/9/25 5:45:24 PM ET
    $RWAY
    $SWKH
    Finance: Consumer Services
    Finance
    Diversified Financial Services

    Callodine Group Appoints Winston Black as Head of Life Sciences Finance Strategy

    Callodine Group ("Callodine") is pleased to announce the appointment of Winston Black as the Head of Callodine's newly formed Life Sciences Finance Strategy. In this role, Mr. Black will lead the firm's efforts in sourcing, underwriting, and managing structured investments across the life sciences sector, with a focus on commercial-stage companies. Mr. Black brings more than 25 years of investment and operational experience, with deep domain expertise in life sciences finance. He has been active in the space since 2005 and has invested over $1 billion in similar strategies across the capital structure. His proven ability to navigate complex transactions and his established network of clin

    7/31/25 8:30:00 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    ImpediMed Secures $15m Growth Capital Funding

    New round will help fuel commercialization efforts in support of ImpediMed's platform technology for the detection and monitoring of lymphedema. CARLSBAD, Calif., Feb. 7, 2025 /PRNewswire/ -- ImpediMed, a leader in medical technologies to clinically monitor and manage fluid and body composition, today announced an agreement for a five-year $15 million growth capital facility with SWK Holdings (NASDAQ:SWKH), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies. Funds raised will provide ImpediMed with funding flexibility and will be used to support growth and commercialization activities. Armentum Partners acted as the Company's exclusiv

    2/7/25 11:00:00 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    Leadership Updates

    Live Leadership Updates

    View All

    Callodine Group Appoints Winston Black as Head of Life Sciences Finance Strategy

    Callodine Group ("Callodine") is pleased to announce the appointment of Winston Black as the Head of Callodine's newly formed Life Sciences Finance Strategy. In this role, Mr. Black will lead the firm's efforts in sourcing, underwriting, and managing structured investments across the life sciences sector, with a focus on commercial-stage companies. Mr. Black brings more than 25 years of investment and operational experience, with deep domain expertise in life sciences finance. He has been active in the space since 2005 and has invested over $1 billion in similar strategies across the capital structure. His proven ability to navigate complex transactions and his established network of clin

    7/31/25 8:30:00 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

    January 22, 2025 Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announced today the appointment of Dr Gary A. Shangold as Chief Medical Officer with immediate effect. Commenting, Stephen Stamp, CEO and CFO of Biodexa said: "I am delighted to welcome Gary to the team. As Biodexa moves towards the later clinical stages including an upcoming global Phase 3 registrational study in FAP, it is essential we access specialists

    1/22/25 8:30:00 AM ET
    $BDRX
    $JNJ
    $SWKH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Diversified Financial Services
    Finance

    SWK Holdings Appoints Chief Financial Officer

    Company Also Promotes Controller DALLAS, TX / ACCESSWIRE / July 8, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, is pleased to announce the appointment of Adam C. Rice, CPA, as Chief Financial Officer (CFO) of the company and the promotion of Courtney Baker, CPA, to Controller.With over 18 years of senior-level finance and accounting leadership experience, Rice has led financial operations management, corporate financial planning and analysis, strategic planning and financial statement reporting. He was previously CFO of Park Cities Asset Management, an SEC

    7/8/24 5:00:00 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    $SWKH
    Financials

    Live finance-specific insights

    View All

    Runway Growth Finance Corp. to Acquire SWK Holdings Corporation

    Acquisition of high-quality portfolio centered on healthcare and life sciences investments Accelerates strategy to diversify and optimize portfolio while adding significant scale Enhances financial profile and is expected to be accretive to net investment income ("NII") MENLO PARK, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (NASDAQ:RWAY) ("Runway Growth" or the "Company"), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today announced that it has entered into a definitive merger agreement to acquire SWK Holdings Corporation (NASDAQ:SWKH) ("SWK"), a life science focused specialty fi

    10/9/25 5:45:24 PM ET
    $RWAY
    $SWKH
    Finance: Consumer Services
    Finance
    Diversified Financial Services

    SWK Holdings Corporation Announces Financial Results for Third Quarter 2024

    Conference Call Scheduled for Friday, November 15, 2024, at 09:00 a.m. CSTCorporate HighlightsThird quarter 2024 GAAP net income was $3.5 million, compared with GAAP net income of $4.5 million for the third quarter 2023.Third quarter 2024 finance receivables segment adjusted non-GAAP net income was $5.0 million, compared with adjusted non-GAAP net income of $5.8 million for the third quarter 2023.As of September 30, 2024, net finance receivables were $255.9 million, a 14.4% increase from September 30, 2023.The third quarter 2024 effective yield was 14.6%, a 60 basis points increase from third quarter 2023.As of September 30, 2024, GAAP book value per share was $22.94, a 3.7% increase from $2

    11/14/24 4:15:00 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    SWK Holdings Provides Portfolio Update

    Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results

    10/17/24 4:15:00 PM ET
    $BTCY
    $DERM
    $ELUT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $SWKH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SWK Holdings Corporation

    SC 13G/A - SWK Holdings Corp (0001089907) (Subject)

    11/14/24 11:49:47 AM ET
    $SWKH
    Diversified Financial Services
    Finance

    Amendment: SEC Form SC 13D/A filed by SWK Holdings Corporation

    SC 13D/A - SWK Holdings Corp (0001089907) (Subject)

    10/25/24 4:05:56 PM ET
    $SWKH
    Diversified Financial Services
    Finance

    SEC Form SC 13G/A filed by SWK Holdings Corporation (Amendment)

    SC 13G/A - SWK Holdings Corp (0001089907) (Subject)

    2/14/24 2:14:12 PM ET
    $SWKH
    Diversified Financial Services
    Finance